SEATTLE, April 24, 2013 /PRNewswire/ -- Plandai
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced
arrival of the first shipment of factory equipment to its
production facility in South Africa. The processing line will
be used in the Company's proprietary extraction process, which
produces botanicals with a higher degree of bioavailability than
other botanical phytonutrients on the market.
Installation, calibration and testing of the equipment is
expected by August with the processing and extraction facility
expected to be ready for the first harvest in November
2013.
"Shipment of this equipment is an important first step in the
ramping up of production at our production facility in South Africa," said Roger Duffield, Chairman and Chief Executive
Officer of Plandai Biotechnology. "With distribution
agreements already in place, we are looking forward to increased
production as levels of tea leaf harvesting increases."
Plandai Biotechnology, through its wholly owned subsidiaries,
farms over 7,500 acres of luscious land in the Mpumalanga province
of South Africa. The Company is currently farming 1,000 acres
of tea bushes, increasing to 2,200 acres over the next five
years.
In published USDA studies, Plandai's proprietary plant extracts,
including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex
and Phytofare™ Carotenoid Extract, have shown to have improved
bioavailability – the degree to which a substance becomes available
to the target tissue after administration – of between 60-80%, far
exceeding anything available today. Superior levels of
bioavailability simply mean that the body can actually receive the
benefits promised on the product label.
The Company believes that its technology is the foundation for
creating an entirely new family of botanical drugs that can treat a
multitude of diseases and conditions safely and affordably using
naturally-derived extracts.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandai Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South
Africa, to producing its patented Phytofare™ extracts
in-house, allowing the Company to guarantee the continuity of
supply as well as quality control throughout the entire
process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandai's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandai is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaibiotech.com
SOURCE Plandai Biotechnology, Inc.